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Abstract 
Background: Heart failure with preserved ejection fraction (HFpEF) is a complex 
disease underlined by impaired ventricular-vascular coupling (VVC). 
Objectives: To evaluate the VVC ratio in HFpEF patients at rest and during exercise 
and compare it to the healthy and heart failure with reduced ejection fraction (HFrEF) 
controls.  
Methods: PubMed and EMBASE databases were searched for trials that matched 
the inclusion criteria. Random-effects models were used to estimate the pooled 
mean difference with 95% confidence interval using Open Meta[Analyst] software.  
Results: A total of 13 trials met the inclusion criteria. Although VVC ratio was 
comparable between HFpEF and healthy controls at rest, it was significantly lower in 
HFrEF compared to HFpEF. During exercise, there was a significant decline in VVC 
ratio in HFpEF (-0.119, 95% CI (-0.183 to -0.055), p<0.001). 
Conclusion: VVC ratio, although ‘preserved’ at rest in HFpEF patients, was overtly 




Ventricular-vascular coupling (VVC) 
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Introduction 
 
Heart failure with preserved ejection fraction (HFpEF) is a challenging and  
significant public health problem 1. It has now been reported  to be the most common 
type of heart failure 1,2, with the prevalence relative to heart failure with reduced 
ejection fraction (HFrEF), increasing at an alarming rate of 1% per year 1. 
Epidemiological studies 2–4 support a heterogeneous group of HFpEF patients who 
generally tend to be older women with multiple co-morbidities such as chronic 
hypertension, obesity, atrial fibrillation and diabetes mellitus. The heterogeneity of 
patients is mirrored by the complex, deranged physiological mechanisms underlying 
HFpEF, one of which is believed to be deranged ventricular-vascular coupling (VVC) 
5–9.  
 
The cardiovascular system is required to provide adequate pressure and flow to the 
body at rest and during periods of stress10,11. To accompany the changes in cardiac 
output and to prevent broad fluctuations in blood pressure, which can inevitably lead 
to vascular and end-organ damage, there needs to be a compliant relationship 
between the left ventricle and the arterial system10. This interaction, termed as 
ventricular-vascular coupling (VVC), is a fundamental marker of the cardiovascular 
performance 10,12. It is estimated as a ratio of arterial elastance (Ea) to end-systolic 
elastance (Ees). Ea is an integrative index of the arterial load 13 whereas Ees is a 
coupled measure of left ventricular contractile function and systolic stiffening 5,14 
estimated using validated non-invasive single-beat methods. One of these methods, 
described by by Chen et al 14 which relies on measurement of non-invasive systolic 
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and diastolic arterial blood pressures, estimated normalised ventricular elastance at 
the onset of ejection and stroke volume derived from Doppler echocardiogram.  
 
Although VVC has been studied extensively 5–7,15,16, there is no systematic review 
examining the VVC ratio in patients with HFpEF compared to the controls and HFrEF 
patients. We therefore provide the first systematic review and meta-analysis for the 
evaluation of VVC and its components in the patients, which may provide a novel 
perspective into the pathogenesis of HFpEF and facilitate a focused approach 
towards the diagnosis of the patients. Thus, the aim of this review is to assess the 
ventricular-vascular coupling ratio and its components in patients with HFpEF 
compared to controls and HFrEF. 
 
Methods 
Our systematic review was conducted and reported in accordance to the Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) guidelines. 
We created a search strategy based around the concepts of heart failure and 
ventricular vascular coupling. A search of PubMed and EMBASE was performed 
from inception until February 2018 using the key terms: “Heart failure”, “preserved 
ejection fraction”, “normal ejection fraction”, “diastolic heart failure”, “HFpEF”, 
“ventriculovascular coupling” and “ventriculovascular interaction”. There were no 
restrictions imposed on language. The full search strategy is included in Appendix A. 
 
Two authors (RB and BL) reviewed the articles independently. Any disagreements 
were resolved by discussion with a third author (VV). The search results from the 
databases were merged into a document and duplicates were removed. All the 
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articles identified in our search were screened using the titles and the abstracts. Any 
article identified as having a potential of fulfilling our inclusion criteria underwent full-
text evaluation. Multiple reports from the same study were carefully searched for and 
removed. 
 
European Society of Cardiology (ESC) 17 guidelines for the diagnosis of HFpEF and 
HFrEF were used. The diagnosis for HFpEF includes three main criteria: (1) Clinical 
signs and symptoms of heart failure (2) Left ventricular (LV) Ejection Fraction by 
echocardiography > 50% (3) Raised natriuretic peptides (Brain Natriuretic peptides 
(BNP) > 35pg/mL or N-terminal pro-B-type natriuretic peptide (NT-proBNP) >125 
pg/mL) and at least one of the following criteria: relevant structural heart disease or 
diastolic dysfunction. Studies that defined HFpEF as heart failure symptoms with 
normal ejection fraction was also accepted. HFmrEF (Heart failure with mid-range 
Ejection Fraction), a new category for patients with EF (40-49%) was excluded from 
the meta-analysis.  
 
Any study design which measured Ea, Ees and VVC ratio in adult HFpEF ( 18 years) 
was included, except for narrative reviews or editorials, including any opinion-based 
publications. Studies published in languages other than English were excluded. 
Trials reporting on the same population were entered as a single study, considering 
the manuscript with the largest patient numbers.  
 
After the eligible studies were identified, data were collected using data extraction 
forms. The following data were extracted from each included study: (1) General 
information: Author names, article title, trial registration, year of publication, type of 
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study, sources of funding (2) Characteristics of the participants: number of 
participants and sample size, mean/median age, gender distribution, heart rate, 
pulse pressure, prevalence of co-morbidities (atrial fibrillation, hypertension) (3) 
Methods: recruitment and diagnostic criteria, assessment of blinding (4) 
Interventions (if any) type and level of exercise (5) Outcomes: adjusted and non-
adjusted effect size for outcomes and measurement tool.  
 
The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the included 
trials. Although it is specifically used for cohort and case control studies, it has been 
used previously for cross-sectional studies due to lack of interventions in these types 
of studies 18,19. The scale comprises of three main components for which any study 
can obtain a maximum of four, two and three stars respectively. Trials with a total 
score of 7 or higher are considered to be high-quality studies.  
 
We compared the mean values and standard deviation for both HFpEF patients and 
controls, as well as sample size. The data was analysed using Open Meta[Analyst] 
Software version 10.12 (developed by the Centre for Evidence Synthesis, Brown 
University, School of Public Health, Rhode Island State, USA) 20. Statistical 
heterogeneity between the studies was evaluated by calculating I2 statistics. This 
describes the percentage of the variability in effect estimates that is due to 
heterogeneity rather than sampling error, with a value less than 25% indicating low, 
25% to 75% medium and higher than 75% indicates high heterogeneity 21. Mean 
VVC ± 95% confidence interval (CI) in HFpEF and controls were compared using 
random effects models in case of high heterogeneity; otherwise, the fixed effects 
model was employed. The statistical significance was defined as p<0.05. Funnel 
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plots were used to assess publication bias using Review Manager (RevMan) 




Our search yielded 2172 studies from the database searches (Figure 1). We 
rejected 2132 trials after duplication check and title-abstract screening. A total of 40 
trials underwent full-text evaluation, out of which 26 studies were excluded: Thirteen 
did not have VVC data for HFpEF patients, 4 used same population, 5 had no 
healthy or HFrEF control group and exercise data, and 1 reported data in median 
value. Furthermore, 3 studies that used EF>45% as a threshold for HFpEF patients 
and 4 studies with no control group and exercise data were excluded to keep a 
comparable pool of patients. One study compared VVC ratio in HFpEF patients to 
significantly younger healthy controls. As VVC ratio and its components change with 
age 22,23, this study was excluded.  
 
Thirteen studies were included in the analysis, providing a total of 814 HFpEF 
patients and 367 healthy age-matched controls and 284 HFrEF controls 
(Supplemental file, Table 1). The studies were predominantly non-invasive, one 
study reported invasive data as well, but for the purposes of this meta-analysis only 
the non-invasive data for ease of comparison. Out of 13 studies, 7 trials reported rest 
vs exercise data for HFpEF patients, and 4 studies analysed HFpEF vs HFrEF data. 
Two studies 24,25 categorised HFpEF patients, both of which were used in the 
analysis as study1, study2. All included trials scored >6 (moderate to high) in the 
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Newcastle Ottawa Scale (NOS) (Supplemental file, Table 2). Funnel plot to assess 
publication bias was performed (Supplemental file, Figure 1). 
 
The mean difference in pooled Ea and Ees between HFpEF and healthy age-matched 
controls was estimated as 0.021, 95% CI (-0.105 to 0.147), p= 0.746, I2= 43%, 
Figure 2A and 0.529, 95% CI (-0.182 to 1.241), p= 0.145 I2= 94%, Figure 2B 
respectively.  Six out of nine trials reported ventricular-vascular coupling ratio as 
Ea/Ees. The mean difference between HFpEF and controls in Ea/Ees was 0.001, 95% 
CI (-0.101 to 0.103), p=0.983, I2 = 85% (Figure 2C). One study 26, excluded from the 
meta-analysis, reported VVC as Ees/Ea. Sensitivity analysis of Ea, Ees and Ea/Ees for 
HFpEF vs controls was performed by removing each study individually. This did not 
significantly change the overall results with the exception of Ees when Abramov study 
was excluded (Supplemental file, Figure 2). 
 
During exercise, there was a significant increase in Ea (0.361, 95% CI (0.031 to 
0.692), p=0.03, I2= 92% (Figure 3A)) and indexed Ea (EaI) (0.873, 95% CI (0.228 to 
1.518), p=0.008, I2= 98% (Figure 3B)) in HFpEF patients. A significant difference 
was also noted in Ees (1.650, 95% CI (0.640 to 2.659), p=0.001, I2 = 94% (Figure 
3C) and EesI (5.989, 95% CI (1.061 to 10.917), p=0.017, I2= 99% (Figure 3D) during 
exercise. As a consequence, VVC ratio (Ea/Ees) and indexed VVC ratio (EaI/EesI) 
decreased significantly during exercise (-0.119, 95% CI (-0.183 to -0.055), p<0.001, 
I2 = 31% (Figure 4A) and -0.104, 95% CI (-0.197 to -0.010), p=0.03, I2 = 95% 
(Figure 4B) respectively). 
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Four studies estimated VVC ratio and its components in HFpEF and HFrEF patients. 
There was no significant mean difference in pooled Ea (-0.103, 95% CI (-0.369 to 
0.164), p=0.450, I2 = 69% (Figure 5A)). Pooled Ees, however, was significantly 
raised in HFpEF patients (2.099, 95% CI (1.065 to 3.133), p< 0.001, I2 = 96% 
(Figure 5B). VVC, consequently, was significantly lower in HFpEF patients (-1.270, 
95% CI (-0.910 to -0.631), p< 0.001, I2 = 96% (Figure 5C).   
 
Discussion 
This is the first systematic review and meta-analysis to assess the arterial elastance, 
end-systolic elastance and ventricular-vascular coupling ratio in HFpEF patients 
compared to age-matched healthy and HFrEF controls.  
Pooled Ea, measured non-invasively using cuff pressures, was estimated to be 
similar between HFpEF patients and healthy controls. It is important to highlight that 
the studies with invasive data and statistically younger controls were excluded in this 
meta-analysis, which helped to compare Ea in the age-matched controls. 
Nevertheless, there is evidence of increased arterial stiffening and hence, raised Ea 
in a healthy ageing community 11,27 which is likely to be responsible for the 
comparable Ea in the pooled analysis. Besides, hypertension is a recognised risk 
factor which is known to affect Ea 13,27. More than half of the HFpEF patients had a 
history of hypertension (73% Phan, 100% Desai, 80% Tan, 86% Borlaug), and 
subsequently, a significant number of patients were on antihypertensives 6,25,28,29. It 
is likely that their enhanced blood pressure and arterial stiffness, had been 
neutralised by adequate treatment 23.  
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In addition, Ees assessed using non-invasive ‘single-beat’ method, was raised but not 
to a significant amount in HFpEF patients at rest compared to the healthy controls. 
Subsequently, VVC remained comparable in HFpEF and healthy controls at rest. 
Nevertheless, pooled estimates reflect a near-optimal ventricular-arterial coupling 
ratio at the expense of Ees and Ea 6, consequently leading to ‘preserved’ ejection 
fraction. 
VVC in HFpEF patients, although preserved at rest, displayed an overt impairment 
during exercise, mainly due to an increase in exercise-induced vascular stiffening 
and impaired LV contractile reserve 10,13. Despite a small number of studies with 
dynamic test data, there is compelling evidence that points towards the significance 
of dynamic examination as a diagnostic investigation of HFpEF. 
ESC follows strict criteria for HFpEF diagnosis as outlined above. It also 
recommends invasive measurements of filling pressures or stress tests in cases of 
uncertainty. As our study has shown assessing the cardiac function of patients with 
exercise intolerance exclusively at rest risks concealing various haemodynamic 
impairments, and perhaps, under-diagnosing HFpEF. There is also evidence to 
support the hypothesis that the initial stage of HFpEF is characterised by normal 
resting but abnormal exercise haemodynamic parameters 30. Multiple studies have 
shown evidence for the prognostic value of cardiopulmonary exercise testing in 
HFpEF 31,32. The present review also advocates the utility of haemodynamic exercise 
testing to identify the population of patients with less advanced HFpEF. 
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The pathogenesis of HFpEF and HFrEF has been a debated topic mainly because 
the therapies that work effectively in HFrEF have not been improving outcomes in 
HFpEF 33. Our study demonstrated a comparable Ea in both heart failure patients, 
despite HFpEF commonly associated with systolic hypertension, but only one trial 34 
reported significantly higher patients on anti-hypertensive therapy in HFrEF than 
HFpEF. Additionally, our study showed a significantly raised end-systolic elastance 
in HFpEF and subsequently reduced VVC but a similar Ea compared to HFrEF at 
rest. Whether the increased Ees exclusively reflects higher contractility is less clear, 
as concentric hypertrophy and passive ventricular stiffening, processes commonly 
observed in HFpEF 35,36, contributes to increased Ees 10. Even though it is vital to 
exhibit additional caution while interpreting the significance of elevated Ees in HFpEF 
participants 16, It begs to suggest that the contractility and the stiffness of the 
chamber perhaps play a significant role in the distinction between HFpEF and 
HFrEF. 
This disproportionate rise in Ees compared to Ea has various clinical implications. A 
rise in Ees accompanies an increase in the systolic pressure, which is believed to be 
the culprit for the enhanced sensitivity to circulating volume in HFpEF patients 14. 
This effect worsens the hypertensive stress responses 5,14,15, characterised by an 
inappropriate rise in systolic BP during exercise 37. Any adjustment in LV end-
diastolic volume, causes a dramatic change in arterial pressures, inducing blood 
pressure lability 14. It explains the rapid-onset pulmonary oedema 5 commonly seen 
in the elderly and even HFpEF patients, on diuretics therapy 14, which is well 
tolerated by HFrEF patients. Future clinical trials should focus on drugs that act on 
ventricular stiffness and afterload 38.One such trial (PRESERVED-HF trial, 
NCT03030235) aims to evaluate the effects of dapagliflozin, a primarily anti-diabetic 
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drug, on exercise capacity in HFpEF patients. Dapagliflozin not only inhibits sodium-
glucose cotransporter-2 and enhances glucose excretion but also improves 
myocardial energetics by reducing afterload and LV load 39. 
 
The present study is the first systematic review and meta-analysis to outline the VVC 
ratio and its components in HFpEF compared to age-matched healthy and HFrEF 
controls. Nevertheless, there are a few limitations to the review. The meta-analysis 
included very few studies owing to strict inclusion criteria in an attempt to include 
comparable group of patients. Multiple studies lacked a control group, limiting our 
analysis to a relatively smaller number of studies, and the studies were non-
randomised which introduces bias. Similarly, there was insufficient data to conduct 
further analyses such as changes in VVC ratio and diastolic response in controls 
during exercise which would have been significant. Ea and Ees were inconsistently 
adjusted, so the multivariate adjustments could not be produced across the studies. 
In addition, heterogeneity, despite our best endeavour, persisted among the studies. 
Despite undertaking random-effects analysis to account for heterogeneity, the 
variable diagnostic criteria for HFpEF disrupted the homogeneity even further. Whilst 
most studies used ESC guidelines to define HFpEF, other studies simplified their 
criteria by combining patients with heart failure symptoms and normal systolic 
function, endangering the uniformity of the patients. Future research should steer 
clear from exclusively LVEF-based HFpEF patients and emphasise on a uniform, 
well-defined cohorts. 
 
In conclusion, impaired ventricular-vascular coupling, one of the distinctive 
mechanisms underlying HFpEF, is mainly apparent on exercise. This calls for a 
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change in the diagnostic guidelines to signify the contribution of dynamic testing, 
data for which are quite in scarce. Further studies are warranted to examine these 
components during exercise on well-defined HFpEF patients.  
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Figure legends: 
Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram of the trial selection process.  
VVC, ventricular-vascular coupling; HFpEF, Heart failure with preserved ejection 
fraction; HFrEF, Heart failure with reduced ejection fraction. 
 
Figure 2: Pooled mean difference in Ea (A), Ees (B) and VVC ratio (C) between 
HFpEF and age-matched healthy controls at rest using random-effect model.  
CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; Ea, 
arterial elastance; Ees, end-systolic elastance; VVC, ventricular-vascular coupling. 
 
Figure 3: Pooled mean difference in Ea (A), EaI (B), Ees (C) and EesI (D) during 
exercise in HFpEF using random-effect model.  
CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; Ea, 
arterial elastance; Ees, end-systolic elastance; EaI, indexed arterial elastance; EesI, 
indexed end-systolic elastance. 
 
Figure 4: Pooled mean difference in Ea/Ees (A) and EaI/EesI (B) and during exercise 
in HFpEF using random-effect model.  
CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; Ea, 
arterial elastance; Ees, end-systolic elastance; EaI, indexed arterial elastance; EesI, 
indexed end-systolic elastance. 
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Figure 5: Pooled mean difference in Ea (A), Ees (B) and VVC ratio (C) between 
HFpEF and HFrEF at rest using random-effect model.  
CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; HFrEF, 
heart failure with reduced ejection fraction; Ea, arterial elastance; Ees, end-systolic 
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